Xu Yipeng, Lou Jianmin, Yu Mingke, Jiang Yingjun, Xu Han, Huang Yueyu, Gao Yun, Wang Hua, Li Guorong, Wang Zongping, Zhao An
Department of Urology, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
Zhejiang Chinese Medical University, Hangzhou, China.
Front Oncol. 2021 Sep 10;11:734587. doi: 10.3389/fonc.2021.734587. eCollection 2021.
Exosomes could be released directly into the urine by the urological tumoral cells, so testing urinary exosomes has great potential for non-invasive diagnosis and monitor of urological tumors. The objective of this study is to systematically review and meta-analysis of urinary exosome for urological tumors diagnosis.
A systematic review of the recent English-language literature was conducted according to the PRISMA statement recommendations (CRD42021250613) using PubMed, Embase, Cochrane Library, Web of Science, and Scopus databases up to April 30, 2021. Risk-of-bias assessment was performed according to the QUADAS 2 tool. The true diagnostic value of urinary exosomes by calculating the number of true positive, false positive, true negative, and false negative, diagnoses by extracting specificity and sensitivity data from the selected literature.
Sixteen eligible studies enrolling 3224 patients were identified. The pooled sensitivity and specificity of urinary exosomes as a diagnostic tool in urological tumors were 83% and 88%, respectively. The area under the summary receiver operating characteristic curve was 0.92 (95% CI: 0.89-0.94). Further subgroup analyses showed that our results were stable irrespective of the urinary exosome content type and tumor type.
Urinary exosomes may serve as novel non-invasive biomarkers for urological cancer detection. Future clinical trial designs must validate and explore their utility in treatment decision-making.
[ https://www.crd.york.ac.uk/prospero/], identifier [CRD42021250613].
外泌体可由泌尿系统肿瘤细胞直接释放到尿液中,因此检测尿液外泌体在泌尿系统肿瘤的无创诊断和监测方面具有巨大潜力。本研究的目的是对尿液外泌体用于泌尿系统肿瘤诊断进行系统评价和荟萃分析。
根据PRISMA声明建议(CRD42021250613),使用PubMed、Embase、Cochrane图书馆、Web of Science和Scopus数据库,对截至2021年4月30日的近期英文文献进行系统评价。根据QUADAS 2工具进行偏倚风险评估。通过计算真阳性、假阳性、真阴性和假阴性的数量,从所选文献中提取特异性和敏感性数据,来确定尿液外泌体的真实诊断价值。
确定了16项符合条件的研究,共纳入3224例患者。尿液外泌体作为泌尿系统肿瘤诊断工具的合并敏感性和特异性分别为83%和88%。汇总的受试者工作特征曲线下面积为0.92(95%CI:0.89 - 0.94)。进一步的亚组分析表明,无论尿液外泌体的内容物类型和肿瘤类型如何,我们的结果都是稳定的。
尿液外泌体可能作为泌尿系统癌症检测的新型无创生物标志物。未来的临床试验设计必须验证并探索它们在治疗决策中的效用。